



Accelerate liquid biopsy analysis with results in 3 days

Rapid insights to help guide toward the future of treatment selection decisions

The Ion Torrent™ OncoPrint™ Pan-Cancer Cell-Free Assay is a targeted next-generation sequencing (NGS) assay that delivers current, clinically relevant insights for 52 oncogenes across 18 different tumor types. Through simultaneous multibiomarker analysis of DNA and RNA from one tube of blood, results are now only three days away.

- **One assay, one workflow, one report**—one liquid biopsy NGS assay simultaneously detects somatic DNA variants, copy number variants, and gene fusions in cell-free, total nucleic acid derived from whole blood; laboratory results can be generated in three days, accelerating your time to report and providing actionable insights to help guide future treatment selection decisions
- **Multiple biomarkers**—one assay detects all classes of variants in 52 oncogenes across 18 different tumor types



Relevant targets supported by labels, guidelines, and clinical trials

Approved labels		Guidelines		Clinical trials				
Hotspots BRAF EGFR KRAS NRAS	CNVs ERBB2 MET Fusions ALK ROS1	Hotspots BRAF EGFR ERBB2 KIT KRAS NRAS PDGFRA	CNVs ERBB2 MET Fusions ALK MET RET ROS1	AKT1 ALK AR ARAF BRAF CCND1 CCND2 CCND3 CDK4	CDK6 CHEK2 DDR2 EGFR ERBB2 ERBB3 ESR1 FBXW7 FGFR1	FGFR2 FGFR3 FGFR4 FLT3 GNA11 GNAQ GNAS HRAS IDH1	IDH2 KIT KRAS MAP2K1 MAP2K2 MET MTOR MYC NRAS NTRK1	NTRK3 PDGFRA PIK3CA PTEN RAF1 RET ROS1 SMO TP53

Ion Torrent™ OncoPrint™

Reporter software—uncovering relevant insights

The OncoPrint Pan-Cancer Cell-Free Assay utilizes high-throughput NGS for analysis across all classes of variants from only one tube of blood. Integrated informatics software enables a comprehensive report that provides contextual insight of sample-specific variants and their use with respect to labels, guidelines, and current global clinical trials (Figure 1).

Strong concordance with tissue enables confidence in your results

Tissue orthogonal concordance was evaluated on plasma samples with corresponding solid tumor molecular characterization. Reported concordance for SNVs and CNVs were shown to be >99%. Key confirmed alterations observed in samples include *EGFR* p.E746_A750del, *EGFR* p.T790M, *EGFR* p.G719S, *KRAS* G12/13, *NRAS* codon 61, *ERBB2* amp, and *EGFR* amp.




Figure 1. Sample report from OncoPrint Reporter links variant data to current labels, guidelines, and clinical trials. Information is provided in an easy-to-consume format.

We are here to help you get started

If your laboratory is interested in a trial evaluation of your samples using the OncoPrint Pan-Cancer Cell-Free Assay or in validating and incorporating the OncoPrint Pan-Cancer Cell-Free Assay into your menu, support is available through the Life Technologies™ Clinical Services Lab (lifelabdx.com or toll-free at 1.888.734.8588).

For more information, go to
thermofisher.com/cfna-assays

ThermoFisher
SCIENTIFIC